Theratechnologies Inc. (THTX) Stock

THTX logo

Theratechnologies Inc.

THTX
Healthcare

Company profile

Theratechnologies reported revenue of $85.87 million for fiscal year 2024. In Q2 2025 (the quarter ended May 31, 2025) revenue was $17.73 million. Its largest business segment, EGRIFTA, brought in 70% of segment revenue in fiscal year 2024; UNITED STATES was the largest region with 100%. In Q2 2025 it reported a net loss of $4.46 million, against net income of $987,000 a year earlier. Our analysis of its filings shows revenue growing from $80.06 million in fiscal year 2022 to $85.87 million in fiscal year 2024, 3.6% a year on average.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss narrowed from $23.96 million in fiscal year 2023 to $8.31 million in fiscal year 2024.
  • Revenue turned down in Q2 2025: down 19.5% from a year before, after a rise of 5.0% in fiscal year 2024.
  • Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended November 30, 2024.

How much revenue does Theratechnologies make?

Theratechnologies reported $85.87 million in revenue for fiscal year 2024, up 5.0% from $81.76 million in fiscal year 2023. In Q2 2025 revenue was $17.73 million.

What is Theratechnologies's largest business segment?

EGRIFTA, with $60.15 million or 70% of segment revenue in fiscal year 2024. Next: TROGARZO Net Sales (30%).

Where does Theratechnologies make most of its revenue?

UNITED STATES: 100% of revenue by region in fiscal year 2024, followed by Europe (under 1%).

What companies are similar to Theratechnologies?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Kalbe Farma Tbk. (KLBF.JK), Alteogen Inc. (196170.KQ), Chugai Pharmaceutical Co., Ltd. (4519.T), DHG Pharmaceutical Joint Stock Company (DHG.VN).

Has Theratechnologies made a profit in recent years?

Net income by fiscal year: FY2020, a loss of $22.67 million; FY2021, a loss of $31.73 million; FY2022, a loss of $47.24 million; FY2023, a loss of $23.96 million; FY2024, a loss of $8.31 million. It reported a net loss in each of these 5 years.

How has Theratechnologies' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, $66.05 million; FY2021, $69.82 million; FY2022, $80.06 million; FY2023, $81.76 million; FY2024, $85.87 million.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Founded1993
IPO DateAug 16, 1996
IPO StatusPublic
FoundersDinesh Patel

Contact & Links

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Theratechnologies Inc. (THTX)”, data as of May 31, 2025, https://dataporium.tech/stocks/THTX

LinkedInLinkedInXXYouTubeYouTube